Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors

Inclusion Criteria: * Breast cancer treated with anti-hormonal therapy based on inhibitors of aromatase (IA) (letrozole, anastrozole or exemestane) ± analogues of the GnRH (aGnRH) * Menopause (natural or induced) and signs / symptoms of vulvovaginal atrophy * Cytology and / or determination of Human Papillomavirus (HPV) negative * Intention or willingness to have sex Exclusion Criteria: * To have received topical hormonal treatment in the last 6 months or Have used vaginal moisturizers and / or lubricants during the 30 days prior to the study treatment * To have received treatment with laser, radiofrequency, hyaluronic acid, etc. in the vagina during the last two years at the beginning of the study * To Have: an active infection of the genital tract; an intraepithelial neoplasm of the cervix, vagina or vulva; suspected of suffering or having been treated for cancer of the genital tract; suffer a genital prolapse of II degree or greater